Continuously infused glipizide reverses the hyperdynamic circulation in ovine endotoxemia.
In advanced sepsis, hemodynamic support is often complicated by a tachyphylaxis against exogenous catecholamines. Although activation of adenosine triphosphate (ATP)-sensitive potassium (K(ATP)) channels plays a pivotal role in the pathogenesis of hyperdynamic vasodilatory shock, previous studies demonstrated only a transient increase in mean arterial pressure (MAP) after bolus administration of K(ATP) channel inhibitors. We hypothesized that a continuous infusion of the sulfonylurea glipizide, a K(ATP) channel inhibitor, may reverse cardiovascular dysfunctions in sepsis permanently. Eighteen adult sheep were instrumented for chronic study. After a baseline measurement in healthy ewes, endotoxin (Salmonella typhosa, 10 ng kg(-1) min(-1)) was continuously infused for 19 h. After 16 h of endotoxemia, the surviving sheep (n = 14) were randomly assigned to be treated with either glipizide (5 mg/kg, followed by a continuous infusion of 8 mg kg(-1) h(-1)) or placebo (normal saline; each n = 7). Measurements of cardiopulmonary hemodynamics, global oxygen transport, acid-base status, and urine output were performed in the healthy state, after 16 h of endotoxemia, and during 3 h of glipizide infusion. Continuous infusion of glipizide reversed the endotoxin-induced hyperdynamic circulation, as indicated by significant increases in MAP and systemic vascular resistance index, as well as decreases in cardiac index and heart rate (P < 0.001 each). In addition, glipizide increased urine output as compared with untreated controls (P < 0.001). The anticipated decrease in glucose plasma levels was prevented by infusion of glucose 5%. From these results, we conclude that continuous glipizide infusion may represent a useful therapeutic option in the treatment of arterial hypotension related to sepsis and systemic inflammatory response syndrome.
Lange
Matthias
M
Department of Anesthesiology and Intensive Care, University of Muenster, Muenster, Germany. lange-m@anit.uni-muenster.de
Williams
William
W
Bone
Hans-Georg
HG
Van Aken
Hugo
H
Bröking
Katrin
K
Morelli
Andrea
A
Hucklenbruch
Christoph
C
Daudel
Fritz
F
Ertmer
Christian
C
Stubbe
Henning
H
Traber
Daniel L
DL
Westphal
Martin
M
D000255:Adenosine Triphosphate / Q000737:chemistry; D000818:Animals; D004195:Disease Models, Animal; D019446:Endotoxemia / Q000188:drug therapy*; D004731:Endotoxins / Q000378:metabolism; D005260:Female; D005913:Glipizide / Q000008:administration & dosage*; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007022:Hypotension / Q000188:drug therapy*; D007249:Inflammation; D007260:Infusion Pumps; D015221:Potassium Channels / Q000378:metabolism; D018805:Sepsis / Q000188:drug therapy; D012756:Sheep; D013577:Syndrome
D004731:Endotoxins; D007004:Hypoglycemic Agents; D015221:Potassium Channels; D000255:Adenosine Triphosphate; D005913:Glipizide